source Post navigation Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes – Yahoo Finance China's PI Certification for Cross-border Data Transfer: What You … – Lexology